Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/ENTPD1 null mice - Wikidata - awgldk - TriplyDB

Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/ENTPD1 null mice

Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/ENTPD1 null mice

http://www.wikidata.org/entity/Q36420128

about

Purinergic signalling and cancer P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients The P2Y2 nucleotide receptor mediates the proliferation and migration of human hepatocellular carcinoma cells induced by ATP.Purinergic signalling during sterile liver injury.P2X7 integrates PI3K/AKT and AMPK-PRAS40-mTOR signaling pathways to mediate tumor cell death.CD39 deficiency in murine liver allografts promotes inflammatory injury and immune-mediated rejection.Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α.Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway.High dose of extracellular ATP switched autophagy to apoptosis in anchorage-dependent and anchorage-independent hepatoma cells.Purinergic signalling in the liver in health and disease.Unlocking the Potential of Purinergic Signaling in Transplantation Regulation of the T Cell Response by CD39.Promising new strategies for hepatocellular carcinoma.Upregulation of BNIP3 mediated by ERK/HIF-1α pathway induces autophagy and contributes to anoikis resistance of hepatocellular carcinoma cells.The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.Purinergic signaling during intestinal inflammation.Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death.Purinergic Signalling: Therapeutic Developments.Role of ADP receptors on platelets in the growth of ovarian cancer.Targeting immunosuppressive adenosine in cancer.P2X7 Receptor Signaling Contributes to Sepsis-Associated Brain Dysfunction.TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex.Targeting adenosine for cancer immunotherapy.Study to evaluate the immunomodulatory effects of radiofrequency ablation compared to surgical resection for liver cancer

P2860

Q24618782-113053C9-BA1B-4C41-922E-98AF300ED728 Q28386398-867B8DBD-9983-4C0D-96EA-97244F710220 Q33846541-3BCF013B-371D-483E-87EB-3511E17B790A Q34035530-24CD0E94-8DFC-4AF0-8673-740597CF37EF Q34658181-741971BB-CF9B-492B-81CB-A05F21B5C2DC Q35202450-882ACC46-8D41-437D-8387-6E89D2E57B9E Q35765467-361E2C5A-A767-435F-ACA8-1EDF02A5A072 Q37251564-2F5B30D0-D811-44A4-A341-DF0ECA31B175 Q37392672-75A24186-D34F-4367-95F6-902647D31E4F Q37468676-775C7C11-D84D-406F-8AF1-412F8A9EFA45 Q38165746-28F53D6D-B7DB-4DC5-A353-CD496A8191F4 Q38785475-101E6CE0-54D0-4912-AED2-60E51B40F45D Q38847228-1EBB009D-ECDB-4E34-BBA9-1D0C28D14BD3 Q38936589-BB32F7CB-F21F-44F3-9150-3E1AA7C101DC Q38972661-F1139F8B-8D7B-4187-B016-2D2AE804B5C7 Q39161005-2105AB17-5E7D-486C-B061-810FE10237B4 Q39331824-33D83202-27BE-49A3-9C12-E8A62EC47DE6 Q42068171-B0FFDDB0-3B4B-4EDB-9DF3-13C02FB610C0 Q42367885-6C37829D-185D-4531-84DC-1D9CD7E2D18B Q45869485-6D3D8F52-F79B-4030-A93F-CA3AACED8DEE Q46140918-92F132FC-85B2-45F5-B716-6E8FDEF4D278 Q46479061-7F4B0F64-CEAC-4D95-8792-C4D0AF69613D Q47716626-4B957C65-E101-49E7-88A0-F05597CC9482 Q55330380-70A8755C-5E6A-498E-8242-AE25B95A0520 Q58798362-1C2DD16F-C29B-48A2-8979-1880FD4831DB

P2860

Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/ENTPD1 null mice

http://www.wikidata.org/entity/Q36420128

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Disordered purinergic signalin ...... ancer in Cd39/ENTPD1 null mice

@ast

Disordered purinergic signalin ...... ancer in Cd39/ENTPD1 null mice

@en

type

label

Disordered purinergic signalin ...... ancer in Cd39/ENTPD1 null mice

@ast

Disordered purinergic signalin ...... ancer in Cd39/ENTPD1 null mice

@en

prefLabel

Disordered purinergic signalin ...... ancer in Cd39/ENTPD1 null mice

@ast

Disordered purinergic signalin ...... ancer in Cd39/ENTPD1 null mice

@en

P1433

Q36420128-0247A35D-BBD7-4B7A-BECC-70576A671787

P1476

Q36420128-2508B961-0EAB-4B48-9BC6-8C919722CFB6

P2093

Q36420128-058F1A85-AEF0-46B9-AEB5-076007F98A30

Q36420128-0F5B297A-09C4-4F44-AF9D-49B481ED03C0

Q36420128-20721715-6616-4050-BC1D-47CE02A842A7

Q36420128-3ACE36F6-20C1-435B-9CBD-4ABD0B5901B2

Q36420128-503FE051-D312-4C49-BAD2-00CF89CF1DE5

Q36420128-5E762D06-2602-4642-9B1C-FB7C988119FD

Q36420128-6F8E8DAB-84EA-4A40-9177-E096972F812A

Q36420128-A0502C78-82A1-4727-A408-A0C8229929FA

Q36420128-B4E24658-7F32-44DB-B56C-FA8CA83214F4

Q36420128-BC094D22-09F3-405C-9CF5-9CF8AF46E1A6

P2860

Q36420128-011558E6-FEDE-4C49-94DF-A5AD4B810DD3

Q36420128-18C0B2C6-492D-428A-888A-5C6018FB08F3

Q36420128-2AA95201-7D6B-41AA-AD0C-7BAC03A580F8

Q36420128-2FAE7A92-D15C-4E8D-A8FB-EEDDAB28BAA0

Q36420128-3F2264F7-F42B-4FA5-A34D-3A9860B3FD11

Q36420128-40259CC5-DE7A-4A12-8D35-0C68C74688AC

Q36420128-4035C4F9-AB9D-4CE7-A820-4C9A5B30B32D

Q36420128-40E5327E-AFEC-47E7-9C37-7D16D623D094

Q36420128-48704A85-DD56-4A7B-9672-3C42995056AF

Q36420128-4BD0C371-0EAB-4EAD-B5E8-6218123C4AFD

P304

Q36420128-F4FC5545-E998-407B-8795-11B2449A5834

P31

Q36420128-D8573045-1C58-47D9-A5F8-AF3FA3E32D71

P356

Q36420128-3E15E3EC-C1A4-467E-8730-C50B4F75B9F4

P407

Q36420128-7CFDD47A-959C-4236-A066-15BD0C008565

P433

Q36420128-114D12C1-4D1B-48E4-90FC-609B3A4FF7F8

P478

Q36420128-CFB025F8-41A1-4D32-93E8-D0266E0BB42B

P50

Q36420128-2CDF81EE-4B1F-4BBE-B641-A504794B42D3

P577

Q36420128-E991E5B7-F949-4B3F-9367-E5AB1DD55729

P5875

Q36420128-C4852DA4-6F83-4D17-A1B9-9BC3EB37C311

P698

Q36420128-AA3212CE-ADC0-4B04-A76E-DAF77F259AA2

P932

Q36420128-480E3CD9-AD8E-46E8-B844-22744604A92A

P356

P1433

P1476

Disordered purinergic signalin ...... ancer in Cd39/ENTPD1 null mice

@en

P2093

Anny Usheva

http://www.w3.org/2001/XMLSchema#string

Elliot B Tapper

http://www.w3.org/2001/XMLSchema#string

Gyorgy Baffy

http://www.w3.org/2001/XMLSchema#string

Lihui Han

http://www.w3.org/2001/XMLSchema#string

Linglin Li

http://www.w3.org/2001/XMLSchema#string

Moritz Schmelzle

http://www.w3.org/2001/XMLSchema#string

Pankaj Seth

http://www.w3.org/2001/XMLSchema#string

Shu Bian

http://www.w3.org/2001/XMLSchema#string

Simon C Robson

http://www.w3.org/2001/XMLSchema#string

Vikas P Sukhatme

http://www.w3.org/2001/XMLSchema#string

P2860

RanBPM associates with CD39 and modulates ecto-nucleotidase activity

The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism

The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway

NF-kappaB inhibition: a double-edged sword in cancer?

Ectonucleotidases of CD39 Family Modulate Vascular Inflammation and Thrombosis in Transplantation

The TOR pathway: a target for cancer therapy

Ras, PI(3)K and mTOR signalling controls tumour cell growth

mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Role of autophagy in cancer

P304

205-216

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.25989

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230615636

http://www.w3.org/2001/XMLSchema#string

P698

22859060

http://www.w3.org/2001/XMLSchema#string

P932

3505255

http://www.w3.org/2001/XMLSchema#string